The most commonly reported adverse events in the Phase 2 trial were gastrointestinal in nature, including nausea, vomiting, and diarrhoea consistent with the GLP-1 receptor agonist class
Dyspepsia, characterized by upper abdominal discomfort, early satiety, or postprandial fullness, may affect a similar proportion of patients and can contribute to reduced caloric intake and weight loss, though it may also impact quality of life if severe or persistent
This is particularly true for potent compounds like Semaglutide or Tirzepatide , where rapid titration can lead to severe gastrointestinal distress
Despite downward pressure on volumes, overall value impact is more balanced due to a clear shift toward premiumization
The Action to Control Cardiovascular Risk in Diabetes trial and the Veterans Affairs Diabetes Trial have shown that while intensive glycemic control may slow the progression of neuropathy, it does not significantly prevent its onset
Journal of molecular medicine (Berlin, Germany), 95(3), 323333